drugset / Trial / NCT05001828
Study of ADI-PEG 20, Venetoclax and Azacitidine in Acute Myeloid Leukemia
Non-randomizedSingle-groupOpen-labelTreatment
Summary
Pegylated arginine deiminase (ADI-PEG 20) will be combined with venetoclax and azacitidine for treatment of subjects with previously treated or untreated with high risk factor acute myeloid leukemia (AML). Venetoclax and azacitidine are front-line therapy for such patients, and ADI-PEG 20 will be added to this regimen in a phase IA/B study.
Timeline
- Start
- 2022-04-05
- Primary completion
- 2026-05
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pegargiminase | Protein / enzyme biologic | — | — |
| Background | Azacitidine | Other / unclassified | — | — |
| Background | Venetoclax | Small molecule | — | — |